EMA Medicine safety communications
Hydroxyprogesterone caproate: post-authorisation measure
Published by European Medicines Agency: · Ref. EMEA-H-A-31-1528
Summary
Post-authorisation measure
- Related referral: Hydroxyprogesterone caproate-containing medicinal products
Medicine
Hydroxyprogesterone caproate
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): hydroxyprogesterone caproate
- Related medicines: Lentogest; Progesterone Retard Pharlon; Proluton Depot
Measures and alternatives
- Regulatory outcome: Suspension
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗